Victoria Gudzak, Charlotte Logeman, Natalie Crown, Anthony N T Ilersich, Mike Folinas, C Meghan McMurtry, Lucie M Bucci, Christine Shea, Vibhuti Shah, Heather Boon, Joel Katz, Lisa Dolovich, Anna Taddio
{"title":"Using the CARD system for university-based pop-up vaccination clinics: A two-stage hybrid effectiveness-implementation study.","authors":"Victoria Gudzak, Charlotte Logeman, Natalie Crown, Anthony N T Ilersich, Mike Folinas, C Meghan McMurtry, Lucie M Bucci, Christine Shea, Vibhuti Shah, Heather Boon, Joel Katz, Lisa Dolovich, Anna Taddio","doi":"10.1080/21645515.2025.2509484","DOIUrl":null,"url":null,"abstract":"<p><p>Mass vaccination clinics efficiently vaccinate large numbers of people. The CARD system (Comfort, Ask, Relax, Distract) is a vaccination delivery framework that can improve the experiences of vaccine recipients and providers. This two-stage hybrid effectiveness-implementation study implemented and sustained CARD in university-based vaccination clinics involving pharmacy student vaccinators. Stage 1 was a before-and-after study conducted across four COVID-19 vaccination clinics in November-December, 2022. Stage 2 was a single cohort study whereby CARD was sustained across four COVID-19/influenza vaccination clinics in November, 2023. In both stages, vaccine recipients rated experiences relative to last vaccination (<i>primary outcome</i>) and symptoms (pain, fear, dizziness) using surveys. Pharmacy student vaccinators completed attitudes and behaviors surveys; a subsample participated in focus groups. In Stage 1, more vaccine recipients in the after period (vs. before) reported a better vaccination experience relative to their last vaccination (64.0% vs 33.6%; <i>p</i> < .001; <i>n</i> = 181). Fear and pain were lower (1.1 vs. 1.7, <i>p</i> = .03; and 1.6 vs. 2.1, <i>p</i> = .02, respectively). In Stage 2, 57.4% (95% CI: 53.1%-61.6%; <i>n</i> = 542) of vaccine recipients reported a better experience. Across stages, pharmacy students had positive attitudes about acceptability, feasibility, and sustainability of CARD and reported high fidelity with CARD-recommended interventions. CARD is recommended for university-based vaccination clinics to improve vaccine recipient and provider experiences.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2509484"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333031/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21645515.2025.2509484","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Mass vaccination clinics efficiently vaccinate large numbers of people. The CARD system (Comfort, Ask, Relax, Distract) is a vaccination delivery framework that can improve the experiences of vaccine recipients and providers. This two-stage hybrid effectiveness-implementation study implemented and sustained CARD in university-based vaccination clinics involving pharmacy student vaccinators. Stage 1 was a before-and-after study conducted across four COVID-19 vaccination clinics in November-December, 2022. Stage 2 was a single cohort study whereby CARD was sustained across four COVID-19/influenza vaccination clinics in November, 2023. In both stages, vaccine recipients rated experiences relative to last vaccination (primary outcome) and symptoms (pain, fear, dizziness) using surveys. Pharmacy student vaccinators completed attitudes and behaviors surveys; a subsample participated in focus groups. In Stage 1, more vaccine recipients in the after period (vs. before) reported a better vaccination experience relative to their last vaccination (64.0% vs 33.6%; p < .001; n = 181). Fear and pain were lower (1.1 vs. 1.7, p = .03; and 1.6 vs. 2.1, p = .02, respectively). In Stage 2, 57.4% (95% CI: 53.1%-61.6%; n = 542) of vaccine recipients reported a better experience. Across stages, pharmacy students had positive attitudes about acceptability, feasibility, and sustainability of CARD and reported high fidelity with CARD-recommended interventions. CARD is recommended for university-based vaccination clinics to improve vaccine recipient and provider experiences.
大规模疫苗接种诊所有效地为大量人群接种疫苗。CARD系统(安慰、询问、放松、分散注意力)是一个疫苗接种提供框架,可以改善疫苗接受者和提供者的体验。这项两阶段混合有效性实施研究在大学疫苗接种诊所实施并维持了CARD,涉及药学专业学生接种员。第一阶段是2022年11月至12月在四个COVID-19疫苗接种诊所进行的前后研究。第二阶段是一项单队列研究,其中CARD于2023年11月在四个COVID-19/流感疫苗接种诊所持续进行。在这两个阶段,疫苗接种者通过调查评估与上次接种疫苗相关的经历(主要结果)和症状(疼痛、恐惧、头晕)。药学专业学生接种员完成态度和行为调查;一个子样本参加了焦点小组。在第一阶段,与上次接种疫苗相比,更多的疫苗接种者在接种后(与之前相比)报告了更好的疫苗接种体验(64.0%对33.6%;p n = 181)。恐惧和疼痛较低(1.1比1.7,p = .03;1.6 vs. 2.1, p =。02年,分别)。在第二阶段,57.4% (95% CI: 53.1%-61.6%;N = 542)的疫苗接种者报告了更好的体验。在各个阶段,药学学生对CARD的可接受性、可行性和可持续性持积极态度,并报告了CARD推荐的干预措施的高保真度。建议在大学疫苗接种诊所使用CARD,以改善疫苗接受者和提供者的经验。
期刊介绍:
(formerly Human Vaccines; issn 1554-8619)
Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics.
Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.